drugset / Trial / NCT01991561
Immunogenicity, Safety, Tolerability of a Plant-made H5 Virus-like-particle (VLP) Influenza Vaccine.
Phase 2
Completed
390 enrolled
Medicago
McGill University Health Centre/Research Institute of the McGill University Health Centre · collabSyneos Health · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
A phase 2, Randomized, Observer-blind, Multicenter, Dose-Ranging Study to Evaluate the Immunogenicity, Safety, and Tolerability of the plant-made H5 VLP Influenza vaccine adjuvanted with Alhydrogel or Glucopyranosyl-lipid adjuvant in squalene emulsion (GLA-SE), in healthy adults 18-60 years of age.
Timeline
- Start
- 2013-06
- Primary completion
- 2014-07
- Completion
- 2014-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aluminum hydroxide | Unknown | — | Other |
| Subject | GLA-SE | Other / unclassified | — | — |
| Subject | H5 VLP vaccine | Vaccine | — | Other |